WHO FCTC Announces Opening of COP10

2Firsts Events by 2FIRSTS.ai
Feb.06.2024
WHO FCTC Announces Opening of COP10
The World Health Organization Framework Convention on Tobacco Control (WHO FCTC) announces the opening of its 10th Conference of Parties (COP10).

The 10th Conference of the Parties (COP10) of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was officially announced on the organization's website on February 5th.

 

The 183 signatories of this convention, representing over 90% of the global population, are collectively working to strengthen and promote tobacco control. Despite the ongoing global population growth in the first two decades of this century, the smoking rate among adults has dropped from nearly 33% to 22%.

 

Dr. Adriana Blanco Marquizo, Director of the Secretariat of the WHO Framework Convention on Tobacco Control, welcomed the participants and raised concerns about the growing prevalence of emerging nicotine and tobacco products.

 

She pointed out that these products "have become a concerning issue, with young people rapidly increasing their usage. One of the reasons is the tobacco industry's misleading information, portraying these products as substitutes for real tobacco control measures. The tobacco industry is once again trying to gain a foothold in addressing the epidemic problem it created and continues to perpetuate.

 

She further urged everyone to be vigilant about the relentless interference of the tobacco industry worldwide, highlighting that "the tobacco industry is attempting to undermine not just COP10, but the efforts of every Conference of the Parties.

 

The Conference of the Parties (COP) is the decision-making body of the World Health Organization Framework Convention on Tobacco Control, comprising of all the treaty's signatories. It regularly reviews the implementation of the convention and makes necessary decisions to promote its effective implementation.

 

The conference will consider a range of actions to guide future work on addressing the global tobacco epidemic, which annually claims the lives of 8.7 million people worldwide, in line with the World Health Organization's Framework Convention on Tobacco Control.

 

The discussion topics at COP10 include:

 

  • Implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control (Regulation of Tobacco Product Ingredients and Disclosure): Report Presented by the Bureau, Expert Group, and WHO  
  • Tobacco Advertising, Promotion, and Sponsorship: Depictions of Tobacco in Entertainment Media: Report Presented by the Working Group  
  • NTPs and Emerging Tobacco Products  
  • Future Tobacco Control Measures (Related to Article 2.1 of the WHO Framework Convention on Tobacco Control)  
  • Implementation of Article 19 of the WHO Framework Convention on Tobacco Control: Responsibilities  
  • Improving the Reporting System of the WHO Framework Convention on Tobacco Control  
  • Implementation Review Mechanism  
  • Contribution of the WHO Framework Convention on Tobacco Control to the Promotion and Realization of Human Rights  
  • WHO Framework Convention on Tobacco Control Investment Fund

Furthermore, discussions on the tobacco control investment fund and the upcoming COP10, scheduled to run from today until Saturday, February 10th, are expected. Following that, the Third Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products (MOP3) is set to take place from Monday, February 12th, to Thursday, February 15th, 2024.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10